Boston Pharmaceuticals, Inc.

Viela Bio, Inc.

Catherine Ettinger

Partha S Chowdhury

Melissa Marie Damschroder

Xiaodong Xiao

Ronald Herbst

Reena Varkey

Stacey Drabic

Qun Du

Ping Tsui

Jodi Karnell

Laura Carter

Brian Michael Naiman

Peter Pavlik

Anna Hansen

Xiao Xiaodong

Yan Chen

Partha Chowdhury

Melissa Damschroder

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.

Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases

Growing community of inventors

Gaithersburg, MD, United States of America

Catherine Ettinger